Dr. Rapoport is a board-certified hematologist and stem cell transplant (SCT) physician, and a trailblazer in the field of regenerative medicine and immunotherapy.
He was among the first to show that combination immunotherapy with vaccine-primed and ex-vivo costimulated autologous T-cells could induce robust vaccine-specific immune responses. He also demonstrated for the first time that early adoptive transfers of costimulated T cells could induce robust T-cell recovery post-transplant in the autologous transplant setting. Most recently he has helped to pioneer the use of genetically engineered T cells to treat multiple myeloma. He has directed six major clinical trials of adoptive T-cells to treat multiple myeloma.
Dr. Rapoport received his bachelor’s degree in biology from Massachusetts Institute of Technology, and his M.D. from Harvard Medical School.